Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92937 | 0.79 | EPHX2 (0.36) | — | |
| SCHEMBL3032831 | 0.76 | L3MBTL1 (0.39) | KMT2A | |
| SCHEMBL13968227 | 0.74 | FFAR1 (0.38) | — | |
| SCHEMBL80871 | 0.70 | KDM1A (0.43) | — | |
| SCHEMBL92929 | 0.68 | POLB (0.32) | — | |
| SCHEMBL8374646 | 0.67 | POLB (0.32) | — | |
| SCHEMBL20794632 | 0.66 | OPRD1 (0.43) | — | |
| SCHEMBL13361648 | 0.66 | LMNA (0.36) | KMT2A | |
| SCHEMBL11990427 | 0.66 | — | — | |
| SCHEMBL19922063 | 0.64 | CHRNB2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129384-B2 | Imidazo[1,2-a]pyrazines as orexin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20110288098-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2011-11-24 | — | — | US | disclosed |
| US-20100267730-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20100160345-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288098-A1 | NOVEL COMPOUNDS | BRD4, HDAC6, ITPR3 | KMT2A 3199/4885 |
| US-20090022670-A1 | NOVEL COMPOUNDS | UGT1A1, UGT2B7, ABCB1 | KMT2A 3634/4885 |
| US-20100267730-A1 | NOVEL COMPOUNDS | BRD4, DPP4, ITPR3 | KMT2A 3658/4885 |
| US-20100160345-A1 | NOVEL COMPOUNDS | BRD4, HDAC6, ITPR3 | KMT2A 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.